Almac Group

What Almac Group does

Almac Group is a privately held, Northern Ireland–headquartered contract development and manufacturing organization (CDMO) founded in 1970, generating approximately £1.1 billion in annual revenue with 7,900+ employees across 18 facilities in Europe, North America, and Asia. The company provides integrated pharmaceutical and diagnostic services across the full drug development lifecycle, operating seven core business units: Almac Diagnostic Services, API Services & Chemical Development, Pharmaceutical Development, Analytical & Solid State Services, Clinical Services, Almac Clinical Technologies, and Commercial Services, plus a wholly owned pharma subsidiary (Galen) and an early-stage drug discovery arm (Almac Discovery). Its customers include top-25 global biopharma and a long tail of biotechs, and Almac states it has contributed to approximately 50% of FDA-approved New Molecular Entities over the past five years and supports 30% of EU approved/pre-registered gene therapy products.

The technology stack spans proprietary software platforms — IXRS3 interactive response technology, WebEZ supply assignment, TempEZ temperature management, Almac One randomization, Almac Trial Coordinator eClinical platform, and the claraT gene expression report — alongside wet-lab capabilities in small molecules, peptides, oligonucleotides, highly potent APIs, biocatalysis (INSIGHT/selectAZyme databases, cGMP flow hydrogenation), and CLIA/CAP/ISO 15189-accredited genomic and companion-diagnostic laboratories. Almac's Northern Ireland base provides unique dual access to EU and UK markets under the Northern Ireland Protocol, and the company holds a uniquely broad regulatory certification stack (CLIA, CAP, ISO 15189, ISO 13485, ISO 17025, EU IVDR, UKCA, FDA 21 CFR Part 820).

Almac monetizes primarily through project-based fee-for-service CDMO contracts and diagnostic service agreements, with revenue generated from API manufacture, formulation development, clinical trial supply and packaging, commercial manufacturing, biomarker and companion-diagnostic development, and IRT/eClinical technology licensing. Go-to-market is direct enterprise sales via regional business development teams (EU, US, APAC) supported by the Almac Gateway client portal, with marketing driven by industry conferences, a knowledge centre, and direct engagement on RFI/RFP processes. Customer concentration is low, with a diversified roster across enterprise pharma and biotech and no disclosed anchor-account dependency.

Name

Almac Group

Legal name

Almac Group

Website

https://almacgroup.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Almac Group is a privately held, Northern Ireland–headquartered CDMO providing integrated drug development, manufacturing, clinical supply, and precision-medicine/diagnostic services to global biopharma and biotech companies across 18 facilities in Europe, North America, and Asia.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO) Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)

Keywords

• Contract pharmaceutical manufacturing
• Clinical trial supply services
• Companion diagnostics development
• API development services
• Biopharmaceutical CDMO services

Headquarters

HQ city

Craigavon

HQ country

United Kingdom

HQ region

Europe

Offices15 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Fee-for-service CDMO model providing integrated pharmaceutical services across the drug development lifecycle, including API manufacture, formulation development, clinical trial supply, and commercial-scale manufacturing. Revenue generated through project-based contracts with biopharmaceutical companies.
2. Diagnostic Services: Precision medicine services including genomic services, biomarker development, companion diagnostics, and clinical testing. Revenue from assay development, validation, and testing services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Almac Group is a contract development and manufacturing organization (CDMO) providing integrated pharmaceutical services across the entire drug development lifecycle. It offers API development and manufacture, formulation development, clinical trial supply and packaging, commercial-scale manufacturing, and precision medicine companion diagnostics. The company serves global biopharmaceutical and biotechnology companies through seven business units operating from 18 facilities across Europe, North America, and Asia-Pacific.

Product overview

Almac Group is a global pharmaceutical services provider offering a comprehensive, integrated platform across the entire drug development lifecycle. The company operates through seven distinct business units: Almac Diagnostic Services (precision medicine and companion diagnostics), API Services & Chemical Development, Pharmaceutical Development, Analytical & Solid State Services, Clinical Services, Almac Clinical Technologies (IRT and eClinical solutions), and Commercial Services. Key products include the IXRS3 interactive response technology platform, Almac Trial Coordinator eClinical platform, TempEZ temperature management system, WebEZ patient supply assignment system, and the claraT gene expression reporting solution. The company provides end-to-end services from early-phase development through commercial manufacturing and distribution, supported by global laboratories (UK, USA, and Asia Pacific) accredited to CLIA, CAP, ISO 15189, and ISO 13485 standards.

Differentiator

Problem solved

Functional benefit

Brands

• IXRS®3: Interactive Response Technology platform for clinical trial management
• TempEZ
• Almac One
• Almac Trial Coordinator
• claraT
• Almac Adapt
• WebEZ
• NeoPeptides
• Galen

Products and services

• Almac Diagnostic Services Precision medicine division providing genomic services, clinical biomarker and companion diagnostics (CDx) development, and global clinical trial testing from CLIA and CAP accredited laboratories for biopharma and biotech companies.
• API Services & Chemical Development Services for all stages of drug development for small molecules (including highly potent), peptides, and oligonucleotides, including API manufacturing, radiolabelling, biocatalysis, and custom synthesis.
• Pharmaceutical Development Expert development and manufacturing solutions for all phases of clinical trials, including early and late-phase formulation development, bioavailability enhancement, and GMP manufacturing.
• Analytical & Solid State Services Comprehensive solutions to support drug substance (API) and drug product development programs, including method development, release testing, stability testing, and solid state services.
• Clinical Services Global clinical supply chain solution covering clinical trial supply, packaging, labelling, distribution, supply chain solutions, and patient-focused services including direct-to-patient delivery.
• Almac Clinical Technologies Clinical trial technology solutions including IXRS3 interactive response technology, eCOA, eConsent, visit management, biostatistics consulting, and Almac ONE randomization and IRT solutions.
• Commercial Services Commercial manufacturing, packaging, serialization, storage, distribution, and pharmaceutical product launch services for the EU market and globally.
• Almac Trial Coordinator eClinical platform launched as part of a $48M investment to improve clinical trial management through interoperability, standardization, and flexibility to address system fragmentation.
• IXRS3 Interactive Response Technology Interactive Response Technology (IRT) platform for managing key components of clinical trials, with configurable features and IRT boosters including ART (drug accountability), OVERSIGHT (trial data integrity), and DCT support.
• WebEZ Fully validated system for assignment of clinical supplies to patients, providing simple patient management options configurable for various clinical trials.
• TempEZ Fully validated temperature management system for clinical supplies, supporting temperature monitoring and excursion reporting.
• claraT Report Unique gene expression report enabling cancer researchers to discover novel insights within pharmacodynamic biomarker discovery by evaluating multiple biologies in parallel.
• Companion Diagnostics (CDx) Development Service End-to-end CDx development, validation, manufacturing, and commercialization services including CDx development and validation, IVD kit manufacturing, and flexible commercialization models.
• Almac PNPLA3 Genotyping Kit Qualitative qPCR-based kit for identification of I148M (rs738409) genotype within the PNPLA3 gene for MASH/MASLD research.
• Specimen Collection & Logistics Service End-to-end clinical trial specimen collection and logistics service including kit design, manufacturing, labelling, supply chain management, and global distribution.
• Specialty Central Lab Service Premium 'white glove' specialty central lab service for end-to-end sample management including specimen processing, storage, and downstream molecular analysis.
• Almac Discovery Research-driven drug discovery company dedicated to development of novel therapeutics using cutting edge research techniques for first-in-class preclinical stage assets.
• Galen Pharmaceuticals Global pharmaceutical company within Almac Group, developing, marketing, and selling medicines worldwide and partnering with other companies for development and commercialization.
• Almac One Patient randomization and IRT solution for supply chain management, facilitating direct-to-patient distribution models.
• Almac Gateway Client Portal Client portal providing access to online services including My Dashboard, My Clinical Supplies, TempEZ, Label Approval System, Depot Network, and Pharma POP.

Quantifiable outcome

• 50% of all FDA approved New Molecular Entities (NMEs) in the last 5 years
• +3 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered core and minor.

• NTRcoreOthers · 16 February 2026Corporate Power Purchase Agreement (PPA) for renewable energy from Murley Wind Farm. Agreement increased clean electricity supply from just under 50% to just under 70% of wind farm output to support Almac's expanded operations at Craigavon headquarters.
• Formosa PharmaceuticalscoreStrategic or Co-development Partner · 6 May 2025Global licensing agreement for development and commercialisation of ALM-401, a first-in-class EGFRxROR1 bispecific antibody-drug conjugate. Almac Discovery will collaborate on preclinical development while Formosa leads clinical development and commercialization.
• AstraZenecacoreStrategic or Co-development Partner · 1 January 2025Companion diagnostics collaboration across multiple chronic disease indications including respiratory, cardiovascular, and metabolic diseases. Strategic partnership for biomarker-driven clinical trials.
• Future Medicines InstituteminorStrategic or Co-development Partner · 4 December 2024Key partnership announced for biomarker and diagnostic collaboration in support of precision medicine development programs.
• EORTC (European Organisation for Research and Treatment of Cancer)minorStrategic or Co-development Partner · 1 January 2023Collaboration established for tumour molecular profiling to support clinical trial programs and precision medicine initiatives.

Scale indicators10 records

Recent moves12 records

Expansion highlights7 records

Direct peers

• Samsung Biologics: Korea-based CDMO specializing in large-scale biologics manufacturing, with growing exposure to gene therapy and ADC modalities. Competes for outsourced advanced therapy manufacturing contracts that increasingly overlap with Almac's service portfolio.
• Lonza Group: Swiss-headquartered global CDMO offering integrated small molecule and biologics API, drug product, and cell & gene therapy services. Lonza is the closest scale and scope comparable to Almac, both serving top biopharma with end-to-end drug development and manufacturing solutions.
• WuXi AppTec (WuXi STA): China-headquartered CRDMO offering API manufacturing, formulation, and analytical services across small molecules and biologics. WuXi STA competes with Almac for global small-molecule CDMO work and is rapidly expanding capacity across modalities.
• Siegfried Holding: Swiss-headquartered CDMO focused on API and finished drug product manufacturing for global pharma. Comparable to Almac's API Services and Pharmaceutical Development divisions in scale and customer overlap.
• Recipharm: European CDMO offering API and drug product manufacturing, particularly in inhalation, sterile injectables, and oral solid dose. Direct competitor to Almac in small-molecule drug product and pharmaceutical development services.
• Catalent: US-based CDMO providing drug substance, drug product, clinical supply, and cell & gene therapy services. Catalent overlaps directly with Almac across formulation development, clinical trial supply, and biologics/oral dose manufacturing for global biopharma.

Emerging players

• Eurofins Scientific: Global bioanalytical and clinical testing services group with growing CDMO exposure. Comparable to Almac Diagnostic Services in clinical trial testing and central laboratory capabilities.

Broad incumbents

• Charles River Laboratories: US-headquartered CRO/CDMO providing discovery, safety assessment, and manufacturing services. Overlaps with Almac Discovery and Almac Sciences in early-stage drug development and biologics support.
• IQVIA: World's largest clinical research services and technology provider, with biotech-facing development and eClinical technology offerings. Competes with Almac Clinical Technologies in IRT, eCOA, and broader eClinical platform markets.
• Thermo Fisher Scientific (Patheon CDMO): Operates one of the world's largest CDMO networks via its Patheon business, offering API, oral solid dose, sterile fill-finish, and clinical trial services. A scaled, publicly listed incumbent competing head-to-head with Almac for global biopharma development contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/AlmacVideo/featured
• LinkedInlinkedin.com/company/11440
• Xx.com/almacgroup

Compliance16 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Almac Group